ArticleNPJ vaccines2025

A randomized phase I trial of intranasal SARS-CoV-2 vaccine dNS1-RBD in children aged 3-17 years.

Kai Chu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.